Newsletter

The global pharmaceuticals market is worth US$300B a year, a figure expected to rise to US$400B within three years. 

Axxess pharma (AXXE) has licensed Monurol a single dose antibiotic, specific treatment for Urinary track infections with Zambon SPA Switzerland. And exclusive license for marketing, and distribution of Trans dermal patches, and cosmetic masks and patches with Caleb Pharma.

Axxess Pharma: a focused healthcare company dedicated to providing a wde range of products to improve the lives of patients and consumers worldwide.

Axxess Pharms  23 wholly-owned prescription and non-prescription products are targeted to improve health-related conditions including several forms of iron deficiency, bone loss, rheumatoid arthritis, migraine headaches, urinary tract infections, infant cradle cap, joint pain and much more.

Axxess Pharma intends to market these products with affordable pricing and widespread availability. Our company will continue to tap the well of innovation to develop ever-more effective and affordable treatment options for the patients we serve, and also foster innovation in education, leadership and advocacy.

Personal passion concerning the well-being of chronic illness sufferers is a major driving force and at the heart of our company. Affordable, proven, prescription and non-prescription products are a critical component to our company Business Plan. We balance environmental impact, social contribution, and financial results. Axxess Pharma is publicly traded under the ticker symbol: AXXE.

wallstreetstallions has been compensated by a third party, five thousand dollars, for this email advertisement.